Regulatory News Roundup: Two Customs Strikes Against MyNicNaxs, U.K. Ad Enforcement
This article was originally published in The Tan Sheet
Two Customs strikes against MyNicNaxs; drug claims and GMP problems; curcumin bioavailability claim nixed; and U.K. ad enforcement news.
You may also be interested in...
Biotek gets FDA's own-labeler lesson; MyNicNaxs shut down after ignoring warning; and FDA sticks with NDI notification cost estimate.
The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.
Japan’s Nichi-Iko has formally entered a business turnaround alternative dispute resolution process that will see the company outline a business rehabilitation plan involving management restructuring and a fresh profit structure, following financial underperformance in the wake of recent quality issues.